Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma

June 4, 2019
Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Approximately 18,000 patients will die from metastatic urothelial cancer in 2019; unfortunately, only 1 in 4 patients benefit from checkpoint inhibition, leaving significant room for improvement in this field, Petrylak explains. A prior phase I trial of enfortumab vedotin showed a 45% overall response rate (ORR) in patients with metastatic disease, which justified an FDA breakthrough therapy designation of the agent.

In this trial, results showed a 44% ORR with a 38% response rate in the liver; the complete response rate was 12%. The agent was also well tolerated, and 12% of patients discontinued treatment due to adverse events. Moreover, a phase III trial is ongoing and is looking at enfortumab vedotin versus platinum-based chemotherapy in patients with metastatic urothelial cancer.

<<< 2019 ASCO Annual Meeting


x